{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:37:27Z","timestamp":1785911847321,"version":"3.56.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2016YFC1303100"],"award-info":[{"award-number":["2016YFC1303100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2016YFC1303100"],"award-info":[{"award-number":["2016YFC1303100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2016YFC1303100"],"award-info":[{"award-number":["2016YFC1303100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shanghai Medical Center of Key Programs for Female Reproductive Diseases","award":["2017ZZ01016"],"award-info":[{"award-number":["2017ZZ01016"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Sciences Foundation of China","doi-asserted-by":"crossref","award":["82172747"],"award-info":[{"award-number":["82172747"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Peritoneal dissemination is the predominant feature of malignant progression in ovarian cancer and is a major cause of poor surgical outcomes and clinical prognoses. Abnormal glycosylation of carbohydrate antigen 125 (CA125) may be involved in peritoneal implantation and metastasis. Here, we evaluated the clinical relevance of CA125-Tn glycoform in the assessment of high-grade serous ovarian cancer (HGSOC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 72 patients diagnosed with HGSOC were included. Pre-treatment serum CA125-Tn levels were measured using an antibody-lectin enzyme-linked immunosorbent assay. The association of CA125-Tn with clinical factors was analyzed in all cases, whereas its association with peritoneal dissemination, residual disease, and progression-free survival was analyzed in stage III\u2013IV cases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Pre-treatment serum CA125-Tn levels were significantly higher in advanced-stage HGSOC patients than in early-stage patients (<jats:italic>P<\/jats:italic>\u2009=\u20090.029). In advanced-stage patients, the pre-treatment CA125-Tn level increased with an increase in Fagotti\u2019s score (<jats:italic>P<\/jats:italic>\u2009=\u20090.004) and with the extension of peritoneal dissemination (<jats:italic>P<\/jats:italic>\u2009=\u20090.011). The pre-treatment CA125-Tn level increased with the volume of residual disease (<jats:italic>P<\/jats:italic>\u2009=\u20090.005). The association between CA125-Tn level and suboptimal surgery remained significant even after adjustment for treatment type and stage. Pre-treatment CA125-Tn levels were also related to disease recurrence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Serum CA125-Tn level could be a novel biomarker for peritoneal dissemination and a promising predictor of surgical completeness in ovarian cancer. Patients with lower CA125-Tn levels were more likely to have no residual disease. CA125-Tn could help surgeons to adopt optimized treatment strategies for patients with advanced ovarian cancer as a pre-treatment evaluator.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13048-022-01066-1","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T09:02:37Z","timestamp":1671786157000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of serum CA125-Tn glycoform in peritoneal dissemination and surgical completeness of high-grade serous ovarian cancer"],"prefix":"10.1186","volume":"15","author":[{"given":"Xiayu","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuefei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congjian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,23]]},"reference":[{"issue":"4","key":"1066_CR1","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian Cancer Statistics 2018. Ca-Cancer J Clin. 2018;68(4):284\u201396.","journal-title":"Ca-Cancer J Clin"},{"key":"1066_CR2","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7\u201333.","DOI":"10.3322\/caac.21654"},{"issue":"9","key":"1066_CR3","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1097\/IGC.0000000000000007","volume":"23","author":"P Amate","year":"2013","unstructured":"Amate P, Huchon C, Dessapt AL, Bensaid C, Medioni J, Belda M, et al. Ovarian cancer sites of recurrence. Int J Gynecol Cancer. 2013;23(9):1590\u201396.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"1066_CR4","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.ygyno.2018.03.043","volume":"149","author":"RN Eskander","year":"2018","unstructured":"Eskander RN, Kauderer J, Tewari KS, Mannel RS, Bristow RE, O\u2019Malley DM, et al. Correlation between surgeon\u2019s assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: an NRG Oncology\/Gynecologic Oncology Group study. Gynecol Oncol. 2018;149(3):525\u201330.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1066_CR5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/annonc\/mdz001","volume":"30","author":"D Dong","year":"2019","unstructured":"Dong D, Tang L, Li ZY, Fang MJ, Gao JB, Shan XH, et al. Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer. Ann Oncol. 2019;30(3):431\u201338.","journal-title":"Ann Oncol"},{"issue":"4","key":"1066_CR6","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3390\/diagnostics11040674","volume":"11","author":"CN Lin","year":"2021","unstructured":"Lin CN, Huang WS, Huang TH, Chen CY, Huang CY, Wang TY, et al. Adding value of MRI over CT in predicting peritoneal cancer index and completeness of cytoreduction. Diagnostics. 2021;11(4):674.","journal-title":"DIAGNOSTICS"},{"issue":"3","key":"1066_CR7","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ygyno.2017.09.021","volume":"147","author":"D Torres","year":"2017","unstructured":"Torres D, Kumar A, Wallace SK, Bakkum-Gamez JN, Konecny GE, Weaver AL, et al. Intraperitoneal disease dissemination patterns are associated with residual disease, extent of surgery, and molecular subtypes in advanced ovarian cancer. Gynecol Oncol. 2017;147(3):503\u201308.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"1066_CR8","first-page":"1234","volume":"115","author":"A du Bois","year":"2009","unstructured":"du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour les Etudes des Cancers de l\u2019Ovaire (GINECO). Cancer-Am Cancer Soc. 2009;115(6):1234\u201344.","journal-title":"Cancer-Am Cancer Soc"},{"issue":"12","key":"1066_CR9","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1080\/14737140.2017.1398088","volume":"17","author":"G Corrado","year":"2017","unstructured":"Corrado G, Salutari V, Palluzzi E, Distefano MG, Scambia G, Ferrandina G. Optimizing treatment in recurrent epithelial ovarian cancer. Expert Rev Anticancer Ther. 2017;17(12):1147\u201358.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"1066_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/carcin\/bgab010","volume":"42","author":"P Giamougiannis","year":"2021","unstructured":"Giamougiannis P, Martin-Hirsch PL, Martin FL. The evolving role of MUC16 (CA125) in the transformation of ovarian cells and the progression of neoplasia. Carcinogenesis. 2021;42(3):327\u201343.","journal-title":"Carcinogenesis"},{"issue":"1","key":"1066_CR11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12885-019-5371-4","volume":"19","author":"X Chen","year":"2019","unstructured":"Chen X, Li XD, Wang XJ, Zhu QY, Wu XL, Wang XP. MUC16 impacts tumor proliferation and migration through cytoplasmic translocation of P120-catenin in epithelial ovarian cancer cells: an original research. BMC Cancer. 2019;19(1):171.","journal-title":"BMC Cancer"},{"issue":"3","key":"1066_CR12","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ygyno.2011.04.032","volume":"121","author":"RC Bast","year":"2011","unstructured":"Bast RC, Spriggs DR. More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis. Gynecol Oncol. 2011;121(3):429\u201330.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1066_CR13","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ygyno.2011.02.020","volume":"121","author":"C Theriault","year":"2011","unstructured":"Theriault C, Pinard M, Comamala M, Migneault M, Beaudin J, Matte I, et al. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. Gynecol Oncol. 2011;121(3):434\u201343.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1066_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.canlet.2006.03.029","volume":"247","author":"N Scholler","year":"2007","unstructured":"Scholler N, Garvik B, Hayden-Ledbetter M, Kline T, Urban N. Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery. Cancer Lett. 2007;247(1):130\u201336.","journal-title":"Cancer Lett"},{"issue":"1","key":"1066_CR15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1476-4598-5-50","volume":"5","author":"J Gubbels","year":"2006","unstructured":"Gubbels J, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006;5(1):50.","journal-title":"Mol Cancer"},{"issue":"2","key":"1066_CR16","doi-asserted-by":"publisher","first-page":"574","DOI":"10.7150\/ijbs.52097","volume":"17","author":"QY Huo","year":"2021","unstructured":"Huo QY, Xu C, Shao YH, Yu Q, Huang LH, Liu YD, et al. Free CA125 promotes ovarian cancer cell migration and tumor metastasis by binding Mesothelin to reduce DKK1 expression and activate the SGK3\/FOXO3 pathway. Int J Biol Sci. 2021;17(2):574\u201388.","journal-title":"Int J Biol Sci"},{"issue":"10","key":"1066_CR17","doi-asserted-by":"publisher","first-page":"9190","DOI":"10.1074\/jbc.M312372200","volume":"279","author":"A Rump","year":"2004","unstructured":"Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, et al. Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004;279(10):9190\u201398.","journal-title":"J Biol Chem"},{"issue":"1","key":"1066_CR18","first-page":"219","volume":"5","author":"P Giannakouros","year":"2015","unstructured":"Giannakouros P, Comamala M, Matte I, Rancourt C, Piche A. MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering beta-catenin signaling. Am J Cancer Res. 2015;5(1):219\u201330.","journal-title":"Am J Cancer Res"},{"issue":"8","key":"1066_CR19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3390\/cancers9080104","volume":"9","author":"Y Klymenko","year":"2017","unstructured":"Klymenko Y, Kim O, Stack MS. Complex determinants of epithelial: mesenchymal phenotypic plasticity in ovarian cancer. Cancers. 2017;9(8):104.","journal-title":"Cancers"},{"issue":"21","key":"1066_CR20","doi-asserted-by":"publisher","first-page":"4227","DOI":"10.1038\/s41388-020-1288-2","volume":"39","author":"TT Kan","year":"2020","unstructured":"Kan TT, Wang W, Ip PP, Zhou ST, Wong AS, Wang X, et al. Single-cell EMT-related transcriptional analysis revealed intra-cluster heterogeneity of tumor cell clusters in epithelial ovarian cancer ascites. Oncogene. 2020;39(21):4227\u201340.","journal-title":"Oncogene"},{"key":"1066_CR21","doi-asserted-by":"publisher","first-page":"10479","DOI":"10.2147\/CMAR.S271596","volume":"12","author":"L Deng","year":"2020","unstructured":"Deng L, Guo SK, Li H, You XH, Song Y, Su HC. CA125, CEA, CA19-9, and Heteroploid cells in Ascites Fluid May help diagnose peritoneal carcinomatosis in patients with gastrointestinal and ovarian malignancies. Cancer Manag Res. 2020;12:10479\u201389.","journal-title":"Cancer Manag Res"},{"issue":"5","key":"1066_CR22","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1136\/ijgc-00009577-200209000-00005","volume":"12","author":"U Saygili","year":"2002","unstructured":"Saygili U, Guclu S, Uslu T, Erten O, Dogan E. The effect of ascites, mass volume, and peritoneal carcinomatosis on serum CA125 levels in patients with ovarian carcinoma. Int J Gynecol Cancer. 2002;12(5):438\u201342.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"1066_CR23","first-page":"188464","volume":"1875","author":"D Thomas","year":"2021","unstructured":"Thomas D, Rathinavel AK, Radhakrishnan P. Altered glycosylation in cancer: a promising target for biomarkers and therapeutics. Bba-Rev Cancer. 2021;1875(1):188464.","journal-title":"Bba-Rev Cancer"},{"issue":"9","key":"1066_CR24","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrc3982","volume":"15","author":"SS Pinho","year":"2015","unstructured":"Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15(9):540\u201355.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"1066_CR25","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41580-020-00294-x","volume":"21","author":"KT Schjoldager","year":"2020","unstructured":"Schjoldager KT, Narimatsu Y, Joshi HJ, Clausen H. Global view of human protein glycosylation pathways and functions. Nat Rev Mol Cell Bio. 2020;21(12):729\u201349.","journal-title":"Nat Rev Mol Cell Bio"},{"issue":"2","key":"1066_CR26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/jalm\/jfz012","volume":"5","author":"L Salminen","year":"2020","unstructured":"Salminen L, Nadeem N, Rolfsen AL, Dorum A, Laajala TD, Grenman S, et al. Exploratory analysis of CA125-MGL and -STn glycoforms in the differential diagnostics of pelvic masses. J Appl Lab Med. 2020;5(2):263\u201372.","journal-title":"J Appl Lab Med"},{"issue":"3","key":"1066_CR27","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.ygyno.2019.12.025","volume":"156","author":"L Salminen","year":"2020","unstructured":"Salminen L, Nadeem N, Jain S, Grenman S, Carpen O, Hietanen S, et al. A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer. Gynecol Oncol. 2020;156(3):689\u201394.","journal-title":"Gynecol Oncol"},{"issue":"9","key":"1066_CR28","doi-asserted-by":"publisher","first-page":"788","DOI":"10.21037\/atm-20-8053","volume":"9","author":"YS Wang","year":"2021","unstructured":"Wang YS, Ren SF, Jiang W, Lu JQ, Zhang XY, Li XP, et al. CA125-Tn ELISA assay improves specificity of pre-operative diagnosis of ovarian cancer among patients with elevated serum CA125 levels. Ann Transl Med. 2021;9(9):788.","journal-title":"Ann Transl Med"},{"issue":"8","key":"1066_CR29","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1245\/ASO.2006.08.021","volume":"13","author":"A Fagotti","year":"2006","unstructured":"Fagotti A, Ferrandina G, Fanfani F, Ercoli A, Lorusso D, Rossi M, et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol. 2006;13(8):1156\u201361.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1066_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ygyno.2016.04.020","volume":"142","author":"G Vizzielli","year":"2016","unstructured":"Vizzielli G, Costantini B, Tortorella L, Pitruzzella I, Gallotta V, Fanfani F, et al. A laparoscopic risk-adjusted model to predict major complications after primary debulking surgery in ovarian cancer: a single-institution assessment. Gynecol Oncol. 2016;142(1):19\u201324.","journal-title":"Gynecol Oncol"},{"issue":"8","key":"1066_CR31","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.3390\/cancers12082238","volume":"12","author":"AA Hassan","year":"2020","unstructured":"Hassan AA, Artemenko M, Tang M, Wong A. Selectins. An important family of glycan-binding cell adhesion molecules in ovarian cancer. Cancers. 2020;12(8):2238.","journal-title":"Cancers"},{"issue":"1","key":"1066_CR32","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1038\/s41467-019-10334-6","volume":"10","author":"S Li","year":"2019","unstructured":"Li S, Ip CKM, Tang MYH, Tang MKS, Tong Y, Zhang J, et al. Sialyl Lewisx-P-selectin cascade mediates tumor\u2013mesothelial adhesion in ascitic fluid shear flow. Nat Commun. 2019;10(1):2406.","journal-title":"Nat Commun"},{"issue":"6","key":"1066_CR33","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/tan.12900","volume":"88","author":"C Fu","year":"2016","unstructured":"Fu C, Zhao H, Wang Y, Cai H, Xiao Y, Zeng Y, et al. Tumor-associated antigens: tn antigen, sTn antigen, and T antigen. Hla. 2016;88(6):275\u201386.","journal-title":"Hla"},{"issue":"39","key":"1066_CR34","doi-asserted-by":"publisher","first-page":"E4066-75","DOI":"10.1073\/pnas.1406619111","volume":"111","author":"P Radhakrishnan","year":"2014","unstructured":"Radhakrishnan P, Dabelsteen S, Madsen FB, Francavilla C, Kopp KL, Steentoft C, et al. Immature truncated O-glycophenotype of cancer directly induces oncogenic features. P Natl Acad Sci Usa. 2014;111(39):E4066-75.","journal-title":"P Natl Acad Sci Usa"},{"issue":"4","key":"1066_CR35","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/IGC.0b013e3182473292","volume":"22","author":"K Akita","year":"2012","unstructured":"Akita K, Yoshida S, Ikehara Y, Shirakawa S, Toda M, Inoue M, et al. Different levels of Sialyl-Tn Antigen expressed on MUC16 in patients with endometriosis and ovarian Cancer. Int J Gynecol Cancer. 2012;22(4):531\u201338.","journal-title":"Int J Gynecol Cancer"},{"key":"1066_CR36","first-page":"D8765","volume":"2","author":"RT Al","year":"2013","unstructured":"Al RT, Lopes AD, Bristow RE, Bryant A, Elattar A, Chattopadhyay S, et al. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2013;2:D8765.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1066_CR37","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.suronc.2017.01.001","volume":"26","author":"H Azais","year":"2017","unstructured":"Azais H, Estevez JP, Foucher P, Kerbage Y, Mordon S, Collinet P. Dealing with microscopic peritoneal metastases of epithelial ovarian cancer. A surgical challenge. Surg Oncol. 2017;26(1):46\u201352.","journal-title":"Surg Oncol"},{"issue":"4","key":"1066_CR38","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nrclinonc.2015.26","volume":"12","author":"AM Nick","year":"2015","unstructured":"Nick AM, Coleman RL, Ramirez PT, Sood AK. A framework for a personalized surgical approach to ovarian cancer. Nat Rev Clin Oncol. 2015;12(4):239\u201345.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"1066_CR39","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.ygyno.2022.03.014","volume":"165","author":"H Lim","year":"2022","unstructured":"Lim H, In Shim J, Park SJ, Noh J, Kim TM, Lee M, et al. Impact of no residual disease on postoperative computed tomography on survival in patients with optimally debulked advanced high-grade serous ovarian cancer during upfront surgery. Gynecol Oncol. 2022;165(3):493\u201399.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1066_CR40","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ygyno.2020.01.010","volume":"157","author":"V Ghirardi","year":"2020","unstructured":"Ghirardi V, Moruzzi MC, Bizzarri N, Vargiu V, D\u2019Indinosante M, Garganese G, et al. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: a survival analysis. Gynecol Oncol. 2020;157(1):209\u201313.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1066_CR41","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ygyno.2014.07.002","volume":"134","author":"RS Suidan","year":"2014","unstructured":"Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Mironov S, Iyer RB, et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol. 2014;134(3):455\u201361.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1066_CR42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ygyno.2017.02.020","volume":"145","author":"RS Suidan","year":"2017","unstructured":"Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Iyer RB, Zhou Q, et al. A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer. Gynecol Oncol. 2017;145(1):27\u201331.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"1066_CR43","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.3802\/jgo.2018.29.e65","volume":"29","author":"Z Feng","year":"2018","unstructured":"Feng Z, Wen H, Jiang Z, Liu S, Ju X, Chen X, et al. A triage strategy in advanced ovarian cancer management based on multiple predictive models for R0 resection: a prospective cohort study. J Gynecol Oncol. 2018;29(5):e65.","journal-title":"J Gynecol Oncol"},{"issue":"4","key":"1066_CR44","doi-asserted-by":"publisher","first-page":"983","DOI":"10.7150\/jca.32317","volume":"11","author":"MY Zhou","year":"2020","unstructured":"Zhou MY, Wang DB, Long ZQ, Zhang Y, Liu J. Role of laparotomy-based Parameters in Assessment of Optimal primary debulking surgery and long-term outcomes in patients with stage IIIC epithelial ovarian cancer. J Cancer. 2020;11(4):983\u201389.","journal-title":"J Cancer"},{"key":"1066_CR45","doi-asserted-by":"crossref","unstructured":"Piedimonte S, Bernardini MQ, Ding A, Laframboise S, Ferguson SE, Bouchard-Fortier G, et al. Integrated prediction model of patient factors, resectability scores and surgical complexity to predict cytoreductive outcome and guide treatment plan in advanced ovarian cancer. Gynecol Oncol. 2022;166(3):453-59.","DOI":"10.1016\/j.ygyno.2022.06.026"},{"issue":"2","key":"1066_CR46","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ygyno.2022.06.010","volume":"166","author":"C Keunecke","year":"2022","unstructured":"Keunecke C, Kulbe H, Dreher F, Taube ET, Chekerov R, Horst D, et al. Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer. Gynecol Oncol. 2022;166(2):334\u201343.","journal-title":"Gynecol Oncol"},{"key":"1066_CR47","doi-asserted-by":"crossref","unstructured":"Kumar A, Wang C, Sheedy SP, McCauley BM, Winham SJ, Ramus SJ, et al. Into the future: a pilot study combining imaging with molecular profiling to predict resectability in ovarian cancer. Gynecol Oncol. 2022;166(3):508-14.","DOI":"10.1016\/j.ygyno.2022.07.020"},{"issue":"2","key":"1066_CR48","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1006\/gyno.2000.5749","volume":"77","author":"DS Chi","year":"2000","unstructured":"Chi DS, Venkatraman ES, Masson V, Hoskins WJ. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol. 2000;77(2):227\u201331.","journal-title":"Gynecol Oncol"},{"key":"1066_CR49","doi-asserted-by":"publisher","first-page":"611617","DOI":"10.3389\/fonc.2020.611617","volume":"10","author":"Y Gu","year":"2021","unstructured":"Gu Y, Qin M, Jin Y, Zuo J, Li N, Bian C, et al. A prediction model for optimal primary debulking surgery based on preoperative computed tomography scans and clinical factors in patients with advanced ovarian cancer: a multicenter retrospective cohort study. Front Oncol. 2021;10:611617.","journal-title":"Front Oncol"},{"issue":"4","key":"1066_CR50","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/j.1525-1438.2007.01064.x","volume":"18","author":"AHMM Arits","year":"2008","unstructured":"Arits AHMM, Stoot JEGM, Botterweck AAM, Roumen FJME, Voogd AC. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer. Int J Gynecol Cancer. 2008;18(4):621\u201328.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"1066_CR51","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1136\/ijgc-00009577-200303000-00003","volume":"13","author":"S Memarzadeh","year":"2003","unstructured":"Memarzadeh S, Lee SB, Berek JS, Farias-Eisner R. CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2003;13(2):120\u201324.","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"1066_CR52","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1158\/1055-9965.EPI-18-0203","volume":"27","author":"BO Akinwunmi","year":"2018","unstructured":"Akinwunmi BO, Babic A, Vitonis AF, Cramer DW, Titus L, Tworoger SS, et al. Chronic Medical Conditions and CA125 levels among women without ovarian cancer. Cancer Epidem Biomar. 2018;27(12):1483\u201390.","journal-title":"Cancer Epidem Biomar"},{"issue":"10","key":"1066_CR53","doi-asserted-by":"publisher","first-page":"e46846","DOI":"10.1371\/journal.pone.0046846","volume":"7","author":"L Shan","year":"2012","unstructured":"Shan L, Chen YA, Davis L, Han G, Zhu WW, Molina AD, et al. Measurement of phospholipids may improve diagnostic accuracy in ovarian cancer. PLoS ONE. 2012;7(10):e46846.","journal-title":"PLoS ONE"},{"key":"1066_CR54","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ejogrb.2016.12.002","volume":"210","author":"M Hirsch","year":"2017","unstructured":"Hirsch M, Duffy J, Deguara CS, Davis CJ, Khan KS. Diagnostic accuracy of Cancer Antigen 125 (CA125) for endometriosis in symptomatic women: a multi-center study. Eur J Obstet Gyn R B. 2017;210:102\u201307.","journal-title":"Eur J Obstet Gyn R B"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-022-01066-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-022-01066-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-022-01066-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T10:08:35Z","timestamp":1671790115000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-022-01066-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,23]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1066"],"URL":"https:\/\/doi.org\/10.1186\/s13048-022-01066-1","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,23]]},"assertion":[{"value":"13 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was approved by the Ethical Committee of Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China. Written informed consent was obtained before surgery.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"YiW, CX and XZ have a patent for CA125-Tn ELISA kit licensed to Obstetrics and Gynecology Hospital of Fudan University. The remaining authors have no conflict of interest in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"134"}}